Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $567.74, for a total transaction of $5,393,530.00. Following the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $23,000,850.62. This represents a 19.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Trading Down 1.3%

NASDAQ:UTHR opened at $570.75 on Thursday. The stock has a market capitalization of $24.23 billion, a PE ratio of 21.07, a price-to-earnings-growth ratio of 1.87 and a beta of 0.60. The firm’s 50 day moving average is $565.54 and its 200 day moving average is $514.75. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period last year, the firm posted $6.63 EPS. Research analysts predict that United Therapeutics Corporation will post 27.07 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. HC Wainwright lifted their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. UBS Group lifted their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Bank of America lifted their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $619.42.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Arjuna Capital grew its position in shares of United Therapeutics by 2.8% during the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after purchasing an additional 18 shares in the last quarter. Clearstead Advisors LLC grew its position in shares of United Therapeutics by 8.9% during the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 23 shares in the last quarter. Sage Rhino Capital LLC grew its position in shares of United Therapeutics by 5.1% during the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after purchasing an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC grew its position in shares of United Therapeutics by 5.4% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after purchasing an additional 24 shares in the last quarter. Finally, Meeder Advisory Services Inc. grew its position in shares of United Therapeutics by 4.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 26 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.